Pharmacological Reports

SEP 22, 2026 · JOURNAL ARTICLE

Transcriptional and epigenetic regulation of the cannabinoid receptor type-1 (CB1R) in health and disease: an overview

Pharmacological Reports

The endocannabinoid system (ECS) is a highly plastic signaling network whose components are dynamically regulated in a context-dependent manner. Among its components, the cannabino

SEP 17, 2026 · JOURNAL ARTICLE

Cancer therapy-related cognitive impairment, part 1: an integrative clinical–mechanistic framework from phenotypes to convergent neurobiological pathways

Pharmacological Reports

Abstract Cancer therapy-related cognitive impairment (CRCI) is a frequent complication of cancer treatment. It involves multiple biological mechanisms: neuroinflammation, oxidative

SEP 11, 2026 · JOURNAL ARTICLE

Cancer therapy-related cognitive impairment, part 2: from bench to bedside—and back: why candidate therapies for cancer therapy-related cognitive impairment fail to translate

Pharmacological Reports

A critical narrative review analyzing why candidate therapies for cancer therapy-related cognitive impairment fail to translate from preclinical to clinical settings, proposing methodological improvements and a translational roadmap rather than reporting original empirical findings.

AUG 12, 2026 · JOURNAL ARTICLE

The course of platinum-based chemotherapy is associated with the risk of hematological complications during poly(ADP-ribose) polymerase (PARP) inhibitor therapy in patients with ovarian cancer

Pharmacological Reports

Retrospective single-centre analysis identifying associations between chemotherapy-induced parameters and PARP inhibitor toxicity, but lacks prospective validation, external cohort confirmation, and actionable clinical thresholds for practice change.